Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

Conversely, a SF <1000 µg/l is associated with a very low likelihood of cirrhosis, making liver biopsy unnecessary ... play a carcinogenic role in hepatocellular carcinoma and other cancers ...

Hepatocellular carcinoma (HCC) is a documented complication ... With all the progress that has occurred, it is interesting that liver biopsy evaluation has retained an essential role in the ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an ...

Researchers describe successful tumor removal through the use of immunotherapy and targeted radiation therapy (TARE), in a patient previously considered ineligible for the procedure.

Using a new technology and computational method, researchers from Fred Hutch Cancer Center and The University of Texas MD ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

This document, on the diagnosis and treatment of patients with hepatocellular carcinoma (HCC), was commissioned by the ... as symptomatic disease in individuals not known to have liver disease, most ...

The leading cause is a viral infection with hepatitis B or C virus. The most frequent liver cancers are hepatocellular carcinoma and hepatoblastoma (formed by immature liver cells).